{"entity":{"id":"nct04730258","kind":"trial","name":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML","aka":[],"tldr":"A phase 1/2 trial of Azacitidine in chronic myelomonocytic leukaemia and mds/mpn overlap neoplasms, run by Treadwell Therapeutics, Inc, active and no longer recruiting.","summary":"A Study of CFI-400945 With or Without Azacitidine in Patients With AML, MDS or CMML is a phase 1/2 interventional study registered as NCT04730258 by Treadwell Therapeutics, Inc, with 72 participants planned, started 2021-04-16 and due to reach its primary completion in 2026-01. Interventions recorded: CFI-400945, Azacitidine. Conditions listed: Acute Myeloid Leukemia, Myelodysplastic Syndromes, Chronic Myelomonocytic Leukemia, AML. No results are recorded here; the registry entry is the source.","status":"active","asOf":"2026-09-16","links":[{"label":"ClinicalTrials.gov NCT04730258","url":"https://clinicaltrials.gov/study/NCT04730258"}],"tags":["ctgov-ingest"],"related":[],"cancers":["cmml"],"sections":[],"technologies":[],"targets":[],"drugs":["azacitidine"],"companies":["treadwell-therapeutics"],"institutions":[],"pathways":[],"terms":[],"trials":[],"people":[],"bottlenecks":[],"keyPapers":[],"journals":[],"notes":[],"nct":"NCT04730258","phase":"1/2","setting":"Phase 1b/2 Clinical Study of the Safety, Tolerability, and Pharmacokinetic and Pharmacodynamic Profiles of CFI-400945 as a Single Agent or in Combination With Azacitidine in Patients With AML, MDS or CMML","sponsor":"Treadwell Therapeutics, Inc","enrolled":72,"outcomes":[]},"route":"/trials/nct04730258/","neighbours":{"cancer":[{"id":"cmml","kind":"cancer","name":"Chronic myelomonocytic leukaemia and MDS/MPN overlap neoplasms","route":"/cancers/cmml/"}],"drug":[{"id":"azacitidine","kind":"drug","name":"Azacitidine","route":"/drugs/azacitidine/"}],"company":[{"id":"treadwell-therapeutics","kind":"company","name":"Treadwell Therapeutics","route":"/companies/treadwell-therapeutics/"}]}}